Correlation Between NYSE Composite and Biomarin Pharmaceutical
Can any of the company-specific risk be diversified away by investing in both NYSE Composite and Biomarin Pharmaceutical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NYSE Composite and Biomarin Pharmaceutical into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between NYSE Composite and Biomarin Pharmaceutical, you can compare the effects of market volatilities on NYSE Composite and Biomarin Pharmaceutical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NYSE Composite with a short position of Biomarin Pharmaceutical. Check out your portfolio center. Please also check ongoing floating volatility patterns of NYSE Composite and Biomarin Pharmaceutical.
Diversification Opportunities for NYSE Composite and Biomarin Pharmaceutical
-0.36 | Correlation Coefficient |
Very good diversification
The 3 months correlation between NYSE and Biomarin is -0.36. Overlapping area represents the amount of risk that can be diversified away by holding NYSE Composite and Biomarin Pharmaceutical in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Biomarin Pharmaceutical and NYSE Composite is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NYSE Composite are associated (or correlated) with Biomarin Pharmaceutical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Biomarin Pharmaceutical has no effect on the direction of NYSE Composite i.e., NYSE Composite and Biomarin Pharmaceutical go up and down completely randomly.
Pair Corralation between NYSE Composite and Biomarin Pharmaceutical
Assuming the 90 days trading horizon NYSE Composite is expected to generate 7.96 times less return on investment than Biomarin Pharmaceutical. But when comparing it to its historical volatility, NYSE Composite is 2.02 times less risky than Biomarin Pharmaceutical. It trades about 0.02 of its potential returns per unit of risk. Biomarin Pharmaceutical is currently generating about 0.09 of returns per unit of risk over similar time horizon. If you would invest 6,545 in Biomarin Pharmaceutical on December 30, 2024 and sell it today you would earn a total of 599.00 from holding Biomarin Pharmaceutical or generate 9.15% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Insignificant |
Accuracy | 100.0% |
Values | Daily Returns |
NYSE Composite vs. Biomarin Pharmaceutical
Performance |
Timeline |
NYSE Composite and Biomarin Pharmaceutical Volatility Contrast
Predicted Return Density |
Returns |
NYSE Composite
Pair trading matchups for NYSE Composite
Biomarin Pharmaceutical
Pair trading matchups for Biomarin Pharmaceutical
Pair Trading with NYSE Composite and Biomarin Pharmaceutical
The main advantage of trading using opposite NYSE Composite and Biomarin Pharmaceutical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NYSE Composite position performs unexpectedly, Biomarin Pharmaceutical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will offset losses from the drop in Biomarin Pharmaceutical's long position.NYSE Composite vs. Corby Spirit and | NYSE Composite vs. Church Dwight | NYSE Composite vs. Nascent Wine | NYSE Composite vs. Crocs Inc |
Biomarin Pharmaceutical vs. Alnylam Pharmaceuticals | Biomarin Pharmaceutical vs. Exelixis | Biomarin Pharmaceutical vs. Halozyme Therapeutics | Biomarin Pharmaceutical vs. Arrowhead Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Complementary Tools
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |